 CytoSorbents Corporation Nasdaq: CTSO the Company, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the pricing of its previously announced underwritten public offering of 5,263,158 shares of its common stock at a public offering price of 9.50 per share, resulting in gross proceeds of approximately 50.0 million before deducting underwriting discounts and commissions and other offering expenses. 